TY  - JOUR
T1  - Bending the curve toward increased use of generic drugs: Comment on “when choosing statin therapy”
AU  - Alldredge BK, Kayser SR
Y1  - 2013/02/11
N1  - 10.1001/jamainternmed.2013.1777
JO  - JAMA Internal Medicine
SP  - 233
EP  - 234
VL  - 173
IS  - 3
N2  - 
Despite the individual and societal benefits associated with lowering drug costs, generic drugs are underused. This is occurring even in the face of compelling evidence from bioequivalence and randomized controlled trials supporting the equivalence of generic drug products1 and efforts from payers to move patients and prescribers toward generics (eg, tiered pharmacy benefits and prior authorization for less cost-effective agents). As Green et al2 point out, the adoption of generic statins to decrease coronary heart disease risk has been slow and disappointingly incomplete, given the equivalence (in terms of clinical efficacy and safety) of generic-available and brand-only statins.

SN  - 2168-6106
M3  - doi: 10.1001/jamainternmed.2013.1777
UR  - http://dx.doi.org/10.1001/jamainternmed.2013.1777
ER  -